MarketPulse

NRX-101

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals, Inc.

NRx Pharmaceuticals to Unveil 2025 Results, Update on Breakthrough Psychiatric Drug Pipeline

NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.
NRXPNRXPWfinancial resultsclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

NRx Pharmaceuticals Names TMS Expert as Chief Medical Innovation Officer

NRx Pharmaceuticals appoints Prof. Joshua Brown, leading TMS researcher, as Chief Medical Innovation Officer to advance PTSD and depression treatments for veterans.
NRXPNRXPWclinical trialsFDA